Final Program as PDF documents: General Program | Friday | Saturday | Sunday

Abstracts as PDF documents: Abstracts Invited Presentations

• The Ongoing Epidemic of Highly Pathogenic Avian Influenza
  J. Lubroth (Italy)
• Present Situation and Clinical Features of A/H5N1 Human Infection
  S. Giriputro (Indonesia)
• Progress on Global Preparedness for Influenza Pandemic, WHO
  N. Shindo (Switzerland)
• Progress on Pre-pandemic/Pandemic Influenza Vaccine
  M. Tashiro (Japan)

• Clinical Implications of Nasopharyngeal Bacterial Colonization
  T. Murphy (USA)
• Antibody Responses Following Administration of 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D-Conjugate Vaccine (PHiD-CV) in Filipino Infants
  N. Bermal, E. Alberto, M. Hernandez, V. Pau (Philippines), A. Fanic (Belgium), S. Gatchalian (Philippines), I. Dieussaert, L. Schuerman (Belgium)
• Impact Estimate of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D-Conjugate Vaccine (PHiD-CV) on Invasive Pneumococcal Disease (IPD) in Middle East and Asian Countries
  N. Begg (Belgium)
• Otitis Media: Why Is it so Difficult to Treat or Prevent?
  G. Navarro-Locsin (Philippines)
• Preventing Pneumonia: Lessons and Future Implications
  R. Dagan (Israel)

• The Challenge of Treating HIV in Asia
  C. Lee (Malaysia)
• The Changing Landscape of HIV Therapies: Increased Choices, Increased Challenges
  A. Carr (Australia)
• ISENTRESS, the First of a New Class of Integrase Inhibitors: Clinical Overview
  C. Hicks (USA)

• Close Encounters of the ETEC-type
  A. Cravioto (Bangladesh)
• Typhoid Vaccines as Routine Public Health Tools for Developing Countries: An Idea Whose Time Has Come
  J. Clemens (Republic of Korea)
• The New Emerging Strain of Cholera: One Step Ahead of Genomics
  G. Balakrish Nair (India)
• Rotavirus and Rotavirus Vaccines: Are We There Yet?
  R. Glass (USA)

• Statins and Sepsis: Multiple Modifications at Multiple Levels
  M. Terblanche (United Kingdom)
• Statins in Animal Models of Infection
  M.W. Merx (Germany)
• Observational Studies of Statins in Bacteremia
  P. Kruger (Australia)
• Parasites as host cholesterol consumers: The special case of Toxoplasma gondii
  K.A. Joiner (USA)

• Clinical and Public Health Impact of Multiple-Resistant Gram-Negative Bacteria
  Y. Carmeli (Israel)
• Epidemiology of Multiple-Resistant Gram-Negative Bacteria in Europe and North America
  A. Srinivasan (USA)
• Burden and Future Gram-Negative Resistance in Asia/Australia
  D.L. Paterson (Australia)
• How to Prevent the Spread of Multiple-Resistant Gram-Negative Bacteria in the Hospital Setting
  S. Harbarth (Switzerland)

• Burden of Pertussis Worldwide: Strategies to Reinforce Pertussis Control in Children, Adolescents, and Adults
  K. Forsyth (Australia)
• Pertussis Control in Infants and Children
  U. Thisyakorn (Thailand)
• The Role of Pertussis Booster Vaccinations in Adolescents and Adults
  D. Johnson (USA)

• Opening Remarks - Adult Immunisation: Some Thoughts
  J. Hanna (Australia)
• Pneumococcal Disease and a Pneumococcal Polysaccharide Vaccine for Older Adults
  M. Mohan (India)
• A Vaccine for the Prevention of Herpes Zoster and Its Complications
  M. Levin (USA)
• Herpes Zoster and Post Herpetic Neuralgia (PHN) - The Taiwan Perspective
  C.C. Yang (Taiwan)
• Herpes Zoster (HZ) and Post-herpetic Neuralgia (PHN): Burden of Illness, Healthcare Utilization, and Costs; the Thai Perspective
  P. Pitisuttihum (Thailand)

• The Changing Epidemiology of Fungal Infection: New Pathogens and Problems
  B. Sathapatayavongs (Thailand)
• Pharmacodynamics of Antifungal Drugs: A Strategy to Optimize Efficacy
  D. Andes (USA)
• New Generation Triazoles: What Do They Offer and When Do We Need Them?
  T.C. Sorrell (Australia)
• Understanding the Similarities and Differences of Existing and Emerging Echinocandins
  M.A. Slavin (Australia)

• Epidemiology of EV71 Outbreaks in the Region in the Past Decade
  A. Kiyu (Malaysia)
• Clinical Studies on EV71 Neurological Disease
  M.H. Ooi (Malaysia)
• Mouse and Non-human Primate Models for EV71 Disease
  H. Shimizu (Japan)
• Update on the Molecular Epidemiology of Human Enterovirus 71 in Taiwan Since 1998
  H.S. Wu (Taiwan)

• CA-MRSA as a Hospital Pathogen
  R. Wenzel (USA)
• Preventing Catheter-Related Bloodstream Infections
  T.M. Perl (USA)
• Relevant Vaccines for Health Care Workers
  S. Ponce de Leon (Mexico)
• Prevention of Surgical Infections
  A. Widmer (Switzerland)

• Multivalent Protection Against a Severe Pediatric Disease - Rotavirus
  C. Christie (Jamaica)
• Long Term Benefits of the Quadrivalent Human Papillomavirus Vaccine (HPV)
  S. Garland (Australia)
• Value of the Quadrivalent HPV Vaccine
  L.L. Villa (Brazil)
• Review of Global and Regional Recommendations for the Pentavalent Rotavirus Vaccine and Quadrivalent HPV Vaccine
  L.L. Villa (Brazil), C. Christie (Jamaica)

• Global Use of Seasonal Influenza Vaccine
  D.S. Fedson (France)
• The Potential Benefits of Intradermal Vaccination
  B.J. Ward (Canada)
• Clinical Development of a Seasonal Influenza Vaccine by Intradermal Micro-injection
  M. Saville (France)
• From Immunogenicity to Vaccine Efficacy: Insights from Statistical and Causal Models
  M.E. Halloran (USA)

• Treatment of Hepatitis C: Yesterday, Today, and Tomorrow
  K.R. Reddy (USA)
• Managing Drug Resistance in the Hepatitis B-Infected Patient
  S.S. Tan (Malaysia)
• Treatment of Hepatitis C in the HIV-Infected Subject
  N. Terrault (USA)
• Metabolic Abnormalities in HIV Infection
  A. Sanyal (USA)

• Genome Analysis
  A.C. Darby (United Kingdom)
• Genetic Variability of Orientia tsutsugamushi
  P.E. Fournier (France)
• The Use of Genomics for the Early Diagnosis of Scrub Typhus and Other Systemic Infectious Diseases
  D. Relman (USA)
• Vector and Epidemiology
  F. Mahara (Japan)

• The spread of hypervirulent Clostridium difficile PCR Ribotype 027 in Europe.
  E.J. Kuijper (Netherlands)
• Diagnosing Clostridium difficile-Associated Diseases: The State of the Art
  C.E. Nord (Sweden)
• Preventing New and Recurrent CDAD
  J. Bartlett (USA)
• Managing CDAD: Current and Upcoming Approaches
  J. Pepin (Canada)

• HPV Types 16, 18, 45 and 31: The Most Important Oncogenic HPV Types Worldwide
  F.X. Bosch (Spain)
• The Value of New Adjuvant Technology
  F. Zepp (Germany), N. Garçon (Belgium)
• Cervical Cancer Vaccination: Protection When and Where It Counts
  T. F. Schwarz (Germany)
• Implementation of Cervical Cancer Vaccination. Reaching Girls and Women: Challenges and Opportunities
  S-K. Tay (Singapore)

• RTI: Treatment Challenges
  S. Esposito (Italy), B. Barsic (Croatia)
• Chlamydia trachomatis: Area Under the Iceberg
  I. Sziller (Hungary)
• Acne vulgaris - Old/New Treatment?
  H. Zelenkova (Slovakia)
• Acute Infectious Gastroenterocolitis: Use or Not to Use Antibiotics?
  D. Vukelic (Croatia)

• Diversity of Human Microbial Pathogens and Commensals
  D. Relman (USA)
• Evolution of Diversity in Pathogen Populations
  M. Eppinger (USA)
• Retroviral Biodiversity: Practical Consequences for HIV Treatment and Prevention
  M. Wainberg (Canada)
• Diversity at the Virus-Bacterium Interface
  D. Raoult (France)

• AIDS in India
  S. Solomon (India)
• AIDS in Thailand
  P. Phanuphak (Thailand)
• AIDS Control in China
  Y. Shao (China)
• AIDS in Malaysia
  A. Kamarulzaman (Malaysia)

• Antimicrobial Practices and Resistance in Pediatrics in an HIV Endemic Area of Cambodia
  J. Benca, L. Seng Duong (Cambodia)
• Antibiotic Practices and Resistance in Genocide Areas of Darfur and Southern Sudan
  V. Krcmery, S. Njabmi (Slovakia)
• Antibiotic Practices and Resistance in a Rural Haitian Population Isolated by Previous Civil War Conflicts
  A. Augustinova (Haiti), K. Holeckova (Slovakia)
• Antibiotic Practices and Policies in Slums of Nairobi and Among Economic Refugees in Turbana Area
  V. Sladeckova, J.M. Muli (Kenya)

• The Origin and Evolution of MRSA
  B. Kreiswirth (USA)
• Evasion of Innate Host Defense by Staphylococcus aureus
  F DeLeo (USA)
• Microbial Pathogenesis of Community-Acquired MRSA Infections
  T.J. Foster (Ireland)
• Clinical Aspects of the Community-Acquired MRSA Epidemic
  H. Chambers (USA)

• Current Discovery Research and Most Promising Avenues, Including Anti-Trypanosomal Screens of Kitasato Natural Products
  H. Yamada (Japan)
• Progress in Discovery and Development of Drug to Treat Dengue Fever
  P. Herrling (Switzerland)
• Improving Malaria Treatment and Compliance - Examining Clinical Evidence on a New Fixed-Dose Combination of Artesunate and Mefloquine
  E. Ashley (Thailand)
• Efficacy and Safety of Artesunate-Amodiaquine Fixed-Dose Combination in India
  N. Valecha (India)
• New Treatment Options for Visceral Leishmaniasis: What's Available and in Clinical Development
  P. Olliaro (Switzerland)

• The Epidemiology of XDR TB in KwaZulu Natal South Africa: A New name or a New Problem
  R. Rustomjee (South Africa)
• MDR-TB and XDR-TB in Asia
  T.E. Tupasi (Philippines)
• Rapid Diagnosis of MDR-TB in Low-resource Settings
  D.A.J. Moore (United Kingdom)
• The Epidemiology of MDR-TB in Peru
  E. Gotuzzo (Peru)

• Measuring Japanese Encephalitis Disease Burden: Challenges in Surveillance and Diagnostics
  M. Fischer (USA)
• Japanese Encephalitis in Indonesia: New Findings on Geographical Extent and Disability from the Disease
  E.R. Sedyaningsih (Indonesia)
• The Landscape of New Vaccines for Japanese Encephalitis: Country-Level Strategies for Introduction
  M.R.N. Abeysinghe (Sri Lanka)
• Japanese Encephalitis Control: What Can Be Achieved?
  J. Hombach (Switzerland)

• International Perspectives on Hospice and Palliative Care for HIV/AIDS
  S.R. Connor (USA)
• Clinical Issues in Palliative Care for HIV/AIDS
  E. Hamzah (Malaysia)
• Successful Development in Hospice and Palliative Care in Asia
  C.R. Goh (Singapore)
• National and International Measurement Opportunities
  D. Casarett (USA)

• How to Evaluate Response to Treatment in AOM
  D.P. McCormick (USA)
• Summary of Studies With New Antibiotics in AOM in Last Decade - Where Are We?
  A. Arguedas (Costa Rica)
• What Do Antibiotics Really Do In AOM?
  R. Dagan (Israel)
• Delayed Antibiotic Treatment of AOM - Risks and Benefits
  P. Little (United Kingdom)

• Multi-resistant Enterobacteriaceae
  J. Turnidge (Australia)
• Carbapenem-resistant Pseudomonas and Acinetobacter
  A. Kamarulzaman (Malaysia)
• Ceftriaxone-resistant Salmonella
  A. Gupta (USA)
• Fluroquinolone-resistant Gonorrhea
  P.R. Hsueh (Taiwan)

• Antimicrobial Resistance Among Anaerobes -The European Experience
  C.E. Nord (Sweden)
• Clostridium difficile Type O27, Coping with a More Virulent Strain
  E.J. Kuijper (Netherlands)
• Molecular Biology of Protein Glycosylation in the Symbiotic Anaerobe Bacteroides Fragilis
  C.M. Fletcher (USA)
• Anaerobes As Biofilms
  G. Donelli (Italy)

• Can Expanded Treatment Slow the AIDS Epidemic? The Public Health Perspective
  N. Kumarasamy (India)
• Can Expanded Treatment Slow the AIDS Epidemic? The Behavioral Scientist's View
  K. Chillag (USA)
• Antivirals in Uninfected People: PrEP and PEP
  A.E. Grulich (Australia)
• Antivirals for HIV Prevention
  K. Mayer (USA)

• Spotted Group Rickettsioses in Asia
  O. Mediannikov (Russia)
• Scrub Typhus
  Y. Suputtamongkol (Thailand)
• Different Clinical Expression of Murine Typhus and Scrub Typhus
  P.N. Newton (Lao People's Democratic Republic)
• Diagnosis of Rickettsioses
  D. Raoult (France)

return to top